Tenderwize
Wróć do wyszukiwania

Open House Discount Agreement Erythropoietin alfa

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jul 03, 2027 · 309 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Erythropoietin alfa, ATC B03XA01

60/100

Ocena szansy

PromisingLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

60 / 100

Złożoność

20 / 100

Czynniki ryzyka

No estimated value or volume commitment; actual business may be minimal.

Open house model is not subject to procurement law; legal remedies are via social courts, not procurement chambers.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Strong opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Non-exclusive discount agreement for Erythropoietin alfa (ATC B03XA01) with AOK Bayern
  • Supply of pharmaceutical products containing the active substance Erythropoietin alfa
Pokaż pełne podsumowanie

Open house non-exclusive discount agreement for the pharmaceutical product Erythropoietin alfa (ATC B03XA01) with AOK Bayern. All interested pharmaceutical companies meeting eligibility criteria can conclude identical, non-negotiable discount agreements. Contracts run from 1 September 2025 to 31 August 2027, with possible termination. This is not a classic procurement procedure but a non-exclusive open-house model under §130a SGB V. No estimated value is published.

Ryzyka

No estimated value or volume commitment; actual business may be minimal.

Open house model is not subject to procurement law; legal remedies are via social courts, not procurement chambers.

Kluczowe wymagania

Eligibility

  • Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible to participate

Administrative

  • Submission of a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
  • Submission of the signed contract including the completed appendix 'Festlegung der vertragsgegenständlichen Arzneimittel'

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria; open house model with equal terms for all.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open House Discount Agreement Erythropoietin alfa

Single lot covering the active substance Erythropoietin alfa. All interested pharmaceutical companies that meet the eligibility criteria can conclude the same discount agreement. The contract can be concluded at any time during the term, latest by 3 July 2027. Submission must be via the communication area of the dtvp portal (not the offer area) or by post with specific deadlines.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Aug 2025 - Aug 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria; open house model with equal terms for all.

Termin

Deadline Jul 03, 2027

Szczegóły zamówienia

Data publikacji
13 Jul 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
458024-2025

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30